KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Pfizer (PFE) EBT Margin (2016 - 2025)

Historic EBT Margin for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to 20.02%.

  • Pfizer's EBT Margin fell 66200.0% to 20.02% in Q3 2025 from the same period last year, while for Sep 2025 it was 30.82%, marking a year-over-year increase of 229100.0%. This contributed to the annual value of 12.61% for FY2024, which is 108300.0% up from last year.
  • According to the latest figures from Q3 2025, Pfizer's EBT Margin is 20.02%, which was down 66200.0% from 20.77% recorded in Q2 2025.
  • Pfizer's 5-year EBT Margin high stood at 172.87% for Q2 2023, and its period low was 120.24% during Q4 2023.
  • Its 5-year average for EBT Margin is 26.73%, with a median of 29.63% in 2021.
  • Its EBT Margin has fluctuated over the past 5 years, first skyrocketed by 1376000bps in 2023, then tumbled by -1498800bps in 2024.
  • Pfizer's EBT Margin (Quarter) stood at 32.63% in 2021, then rose by 22bps to 39.76% in 2022, then tumbled by -402bps to 120.24% in 2023, then surged by 122bps to 26.64% in 2024, then fell by -25bps to 20.02% in 2025.
  • Its EBT Margin was 20.02% in Q3 2025, compared to 20.77% in Q2 2025 and 20.31% in Q1 2025.